Literature DB >> 2833959

Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation.

J R Wingard1, D Y Chen, W H Burns, D J Fuller, H G Braine, A M Yeager, H Kaiser, P J Burke, M L Graham, G W Santos.   

Abstract

Cytomegalovirus (CMV) infection was detected in 65 of 143 (45%) autologous bone marrow transplant (BMT) patients. CMV pneumonitis occurred in only 2% of the patients and CMV retinitis occurred in none. Infection occurred in half of the 40 initially seronegative patients and 47% of the 94 initially seropositive patients. Among initially seropositive patients, platelet recovery was slower in infected patients than in those not infected (97 v 35 days median, P = .003), and neutrophil recovery was slightly delayed in infected patients (31 days v 24 days, P = .02). Although the incidence of CMV infection was comparable in autologous and allogeneic BMT patients, CMV pneumonitis was less frequent in autologous BMT patients (2% v 12%, P less than .001). The risk for CMV pneumonitis in autologous BMT patients was comparable with that in allogeneic BMT patients without graft-v-host disease (GVHD) (2% v 6%), but significantly lower than the risk in allogeneic BMT patients with GVHD (2% v 23%, P less than .001).

Entities:  

Mesh:

Year:  1988        PMID: 2833959

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Control of cytomegalovirus in bone marrow transplantation chimeras lacking the prevailing antigen-presenting molecule in recipient tissues rests primarily on recipient-derived CD8 T cells.

Authors:  M Alterio de Goss; R Holtappels; H P Steffens; J Podlech; P Angele; L Dreher; D Thomas; M J Reddehase
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

2.  Monitoring of cytomegalovirus infection and disease in bone marrow recipients by reverse transcription-PCR and comparison with PCR and blood and urine cultures.

Authors:  J Gozlan; J P Laporte; S Lesage; M Labopin; A Najman; N C Gorin; J C Petit
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

Review 3.  Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.

Authors:  H Hebart; L Kanz; G Jahn; H Einsele
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 4.  Bone marrow transplantation. Part I--Allogeneic.

Authors:  N J Chao; K G Blume
Journal:  West J Med       Date:  1989-12

5.  A cross-Canada survey of cytomegalovirus prevention and treatment practices in bone marrow transplant recipients.

Authors:  A Humar; J Lipton; H Messner; A McGeer; T Mazzulli
Journal:  Can J Infect Dis       Date:  1999-11

6.  Murine model of interstitial cytomegalovirus pneumonia in syngeneic bone marrow transplantation: persistence of protective pulmonary CD8-T-cell infiltrates after clearance of acute infection.

Authors:  J Podlech; R Holtappels; M F Pahl-Seibert; H P Steffens; M J Reddehase
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 7.  Cytomegaloviral virus infection in bone marrow transplantation recipients: strategies for prevention and treatment.

Authors:  H K Holland; R Saral
Journal:  Support Care Cancer       Date:  1993-09       Impact factor: 3.603

8.  Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis.

Authors:  Francisco M Marty; Julie Bryar; Sarah K Browne; Talya Schwarzberg; Vincent T Ho; Ingrid V Bassett; John Koreth; Edwin P Alyea; Robert J Soiffer; Corey S Cutler; Joseph H Antin; Lindsey R Baden
Journal:  Blood       Date:  2007-03-28       Impact factor: 22.113

Review 9.  Viral infections in severely immunocompromised cancer patients.

Authors:  S M Devine; J R Wingard
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

10.  Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation.

Authors:  Satoshi Kaito; Yujiro Nakajima; Konan Hara; Takashi Toya; Tetsuya Nishida; Naoyuki Uchida; Junichi Mukae; Takahiro Fukuda; Yukiyasu Ozawa; Masatsugu Tanaka; Kazuhiro Ikegame; Yuta Katayama; Takuro Kuriyama; Junya Kanda; Yoshiko Atsuta; Masao Ogata; Ayumi Taguchi; Kazuteru Ohashi
Journal:  Blood Adv       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.